New Zealand's medicines regulator has authorized two psychiatrists to prescribe pharmaceutical-grade MDMA within supervised treatment programs for eligible adults with post-traumatic stress disorder. The Ministry of Health announced the decision on September 4, saying the option is intended for a limited number of patients whose symptoms have not responded to conventional therapies.
The authorization permits MDMA-assisted psychotherapy, in which a controlled dose is combined with psychotherapy as one part of a comprehensive treatment plan. Care must take place in a clinical setting under an authorized psychiatrist, and patients will not receive supplies to take home. The product contains the same active ingredient associated with illicit ecstasy but is manufactured to pharmaceutical standards.
Safeguards require patients to be at least 18 and to complete a comprehensive clinical assessment. The two psychiatrists must follow approved therapeutic protocols, obtain informed consent and decide eligibility individually. Medsafe required them to demonstrate substantial expertise and submit detailed plans explaining how treatment would be delivered safely and appropriately.
The Ministry stressed that the decision does not amount to approval of MDMA as a medicine in New Zealand. Evidence for its use in PTSD continues to develop internationally, while authority remains limited to the two named prescribers. Any other clinician seeking to use it must secure separate Medsafe approval, preserving case-specific regulatory oversight.
The move places New Zealand alongside Australia, where authorized psychiatrists have been able to provide MDMA-assisted psychotherapy for PTSD since 2023. It also follows New Zealand's 2025 authorization for a psychiatrist to prescribe medicinal psilocybin for treatment-resistant depression; officials say two clinicians currently hold permission for psilocybin and two for MDMA.
Medsafe said it weighed access to an innovative option against the need to protect patients from harm. The practical impact will initially remain narrow because prescribing is restricted, clinical controls are extensive and the treatment is expected to suit only a small population. Future access will depend on additional individual approvals and the evolving international evidence base.
Comments